HOME >> BIOLOGY >> NEWS
Combination of Lipitor and Celecoxib

Combination of Lipitor and Celecoxib at lower doses is most effective at limiting colon cancer developmentAnaheim, Calif. -- Combinations of Lipitor and Celebrex (celecoxib) at lower doses proved more effective at limiting colon cancer than higher doses of the drugs when given alone, according to research reported at the 96th Annual Meeting of the American Association for Cancer Research here today.

A low dose blend of the non-steroidal anti-inflammatory drug celecoxib and the cholesterol-lowering medication Lipitor dramatically limited the incidence of invasive and non-invasive colon adenocarcinomas, said Bandaru Reddy, D.V.M., Ph.D., research professor at Rutgers University, Piscataway, N.J.

"The combination of these drugs given to laboratory animal models inhibited 95 percent of the tumors that developed in untreated animals," Reddy said. "When used together, the drugs were most effective at doses substantially lower than when used alone.

"Using a combination of low doses of these chemopreventive agents that have differing action may be the most effective way to maximize the anti-cancer effect of the drug while also minimizing toxicity or harmful side effects."

Reddy's studies were conducted in an animal model that closely represents pathogenic, molecular and genetic events that occur in the development of cancer in the human colon. The doses of the drug combination ingested by the experimental rats were the equivalent of 120 mg/day for celecoxib and 40 mg/day for Lipitor.

By itself, celecoxib at 600 parts per million (ppm) in the diet reduced the incidence, as well as the number, of colon adenocarcinomas by 80 percent. Lipitor at 150 ppm alone reduced tumor incidence by 31 to 41 percent.

Together, at only 300 ppm of celecoxib and 100 ppm Lipitor, the drugs reduced invasive and non-invasive adenocarcinomas by 95 percent. Low doses of Lipitor and celecoxib in combination suppressed invasive adenocarcinomas, sugg
'"/>

Contact: Russell Vanderboom, Ph.D.
vanderboom@aacr.org
215-440-9300
American Association for Cancer Research
18-Apr-2005


Page: 1 2

Related biology news :

1. Combination Lyme disease vaccine proteins patented
2. Combination of technologies works best against E. coli
3. Orexigen reports positive phase II results for Excalia Combination-Therapy to treat obesity
4. Combination therapy shows promising results in patients with advanced lung cancer
5. Combination of PET, MR imaging shows white matter degeneration in Huntingtons disease patients
6. Combination therapy for mouse model of human inherited blindness
7. Combination therapy leads to partial recovery from spinal cord injury in rats
8. Combination therapy boosts effectiveness of telomere-directed cancer cell death
9. Combination hormone therapy doubles breast density and quadruples risk of abnormal mammograms
10. VYTORIN (TM) superior again to Lipitor at lowering LDL (bad) cholesterol

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/13/2019)... ... , ... KICVentures announced today its plans to host an event ... ASC Conference in Chicago on Thursday, June 13th at 6:30 pm. The event will ... the 3rd floor Ticino Hospitality room in space #74T. , The event will feature ...
(Date:6/11/2019)... Ind. (PRWEB) , ... June 10, 2019 , ... Improved ... in the July 2019 issue of AAPS PharmSciTech. The article was published online on ... of Improved Pharma, along with Xiaoming Sean Chen of Purdue University. , The ...
(Date:6/6/2019)... ... June 05, 2019 , ... ... the exclusive financial advisor to Pathologists Bio-Medical Laboratories (PBM) on its recent acquisition ... anatomic pathology platform that provides services to more than one dozen hospitals and ...
Breaking Biology News(10 mins):
(Date:5/15/2019)... , ... May 16, 2019 , ... ... mixtures. As a result, food and beverage products rely on these ingredients to ... more natural sounding label declarations. This paradigm shift triggers food formulators to seek ...
(Date:5/8/2019)... , ... May 07, 2019 , ... Standing at 16.2 hands, Atlas is on the ... in a drill team and barrel racing, among other activities. When loping around a ... He went from being a busy horse to only being able to walk. Fortunately ...
(Date:5/4/2019)... ... May 03, 2019 , ... Diopsys Inc, the ... ffERG/Photopic Negative Response vision test, a new full field electroretinography (ffERG) protocol ... that 6.3 million Americans will have glaucoma, with black Americans having the highest ...
(Date:5/2/2019)... ... ... Stay on top of current hot topics through free webinars presented by leading experts ... so be sure to register today to save your place! Participate in the discussion ... upcoming webinars: , CLINICAL TRIALS , May 7 – Oncology Clinical Trials – The ...
Breaking Biology Technology:
Cached News: